Pholprine Cough Linctus
1. Disclaimer
This information is provided for educational and informational purposes only and is intended to provide a scientific overview of Pholprine Cough Linctus and its reported ingredients. It does not constitute medical advice, diagnosis, treatment, prescribing instructions, or a recommendation to use this product. It should not replace the approved product information, package insert, professional clinical judgment, or advice from a qualified physician or pharmacist.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Particular caution is warranted with older medicines because formulations, indications, age restrictions, regulatory status, and availability may change. The current Egyptian Drug Authority (EDA) product record and the labeling of the specific marketed product, where applicable, should take precedence over historical or secondary-source information. The EDA is the Egyptian regulatory authority responsible for the registration, circulation, quality, efficacy, and safety oversight of pharmaceutical products in Egypt.
2. Summary
Pholprine Cough Linctus is an Egyptian cough-and-cold preparation historically associated with Misr and described in Egyptian drug-information sources as a combination containing pholcodine, phenylpropanolamine, promethazine, and tolu syrup. It was classified as an antitussive preparation and supplied as a 125 mL oral liquid.
The pharmacological rationale of the combination is based on suppression of the cough reflex by pholcodine, reduction of nasal congestion by phenylpropanolamine, and antihistaminic/sedative effects from promethazine. Tolu syrup functions primarily as a traditional soothing vehicle/demulcent component rather than as a modern evidence-based expectorant.
However, Pholprine requires particular historical and regulatory caution. Pholcodine-containing medicines were withdrawn from the EU and UK in 2023 following evidence that pholcodine exposure, particularly during the preceding 12 months, is associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents (NMBAs). Australia subsequently cancelled registrations of pholcodine-containing medicines and recalled them.
Phenylpropanolamine also has a significant international safety history because of its association with hemorrhagic stroke, which resulted in its removal or restriction from many markets. The U.S. FDA subsequently determined that phenylpropanolamine was not generally recognized as safe and effective for OTC nasal-decongestant use.
An Egyptian Drug Authority safety communication specifically addressed the pholcodine/NMBA issue and stated that the final ALPHO study demonstrated an association between pholcodine use within the preceding 12 months and peri-anaesthetic anaphylaxis to NMBAs.
Accordingly, Pholprine should be regarded as a historical/legacy product whose exact current formulation, registration status, availability, and approved directions should not be inferred from old online listings.
3. Brand Name
Trade name: Pholprine Cough Linctus
Pack size reported in Egyptian sources: 125 mL
Manufacturer associated with the product: Misr
Some Egyptian online drug databases currently describe the 125 mL product as cancelled, while other pharmacy and drug-information listings continue to display historical product information. These secondary listings should not be interpreted as definitive evidence of current Egyptian registration or availability.
4. Category
Pholprine is a combination cough-and-cold preparation / antitussive containing centrally acting cough suppression, antihistaminic activity, and sympathomimetic decongestant activity.
Its principal pharmacological components are:
- Pholcodine: centrally acting opioid antitussive.
- Phenylpropanolamine: sympathomimetic nasal decongestant.
- Promethazine: first-generation H1-antihistamine with prominent sedative and anticholinergic properties.
- Tolu syrup: traditional soothing/demulcent syrup component.
It is not an antibiotic or antimicrobial medicine.
5. Active Ingredient
Available Egyptian drug-information sources consistently identify the principal active ingredients as:
- Pholcodine
- Phenylpropanolamine
- Promethazine
- Tolu syrup
However, the exact quantitative strengths per 5 mL could not be reliably established from a current primary manufacturer label or publicly accessible current EDA product document during this review.
One historical pharmaceutical-list source contains a conflicting formulation record involving pholcodine, promethazine and pseudoephedrine rather than phenylpropanolamine. Because the evidence is inconsistent and the product appears to be an older/cancelled product in some Egyptian databases, assigning a precise mg/5 mL composition without the original approved label would create a significant risk of misinformation.
Therefore, the exact strength should be taken only from the original Pholprine package insert, manufacturer documentation, or the corresponding EDA-approved product record.
6. Pharmaceutical Form & Strength
Dosage form: Oral liquid / cough linctus / syrup
Reported pack size: 125 mL
The precise quantitative strength of each pharmacologically active ingredient is not sufficiently verified from a current primary source and therefore is intentionally not stated here as a definitive mg/5 mL value.
This is preferable to reproducing conflicting historical strengths from secondary databases.
7. Manufacturer & Marketing Authorization Holder
Pholprine Cough Linctus is historically associated with Misr, an Egyptian pharmaceutical manufacturer. Egyptian drug-information sources identify the manufacturer as Misr.
The exact current legal identity of the marketing authorization holder and the current authorization status could not be independently confirmed from the publicly searchable EDA product interface during this review.
Some Egyptian secondary sources explicitly label the 125 mL product as "cancelled." This should be treated as a secondary-source indication rather than a substitute for confirmation from the EDA regulatory database. The EDA provides an official registered-drug search service and is the appropriate authority for determining current registration and circulation status.
8. Mechanism of Action
Pholcodine
Pholcodine is a centrally acting opioid antitussive. It suppresses coughing principally through action within the central nervous system, increasing the threshold for the cough reflex.
Although pholcodine has historically been regarded as having relatively limited analgesic activity compared with classic opioid analgesics, it should not be described as completely devoid of opioid-related adverse effects. Sedation and respiratory depression can occur, particularly with excessive exposure or combination with other CNS depressants.
Phenylpropanolamine
Phenylpropanolamine is a sympathomimetic amine with predominantly adrenergic effects. Its vasoconstrictor activity reduces nasal mucosal blood flow and edema, thereby producing a decongestant effect.
Because of its sympathomimetic effects, it can also increase blood pressure and heart rate in susceptible individuals.
Promethazine
Promethazine is a first-generation H1-antihistamine of the phenothiazine class. It reduces histamine-mediated symptoms such as rhinorrhea and sneezing and also possesses substantial sedative and anticholinergic activity.
Tolu Syrup
Tolu syrup, traditionally associated with balsam of Tolu, functions primarily as a soothing/demulcent component of cough preparations. Claims of clinically important expectorant activity should not be overstated because modern evidence supporting a major therapeutic effect is limited.
9. Spectrum of Activity
Not applicable as an antimicrobial spectrum.
Pholprine is a symptomatic cough-and-cold preparation and has no direct antibacterial, antiviral, or antifungal activity.
Its intended pharmacological effects relate to cough suppression, reduction of nasal congestion, and relief of selected histamine-mediated upper-respiratory symptoms.
It should not be represented as treatment for the underlying infectious cause of a respiratory illness.
10. Pharmacokinetics
There are insufficient reliable published pharmacokinetic data specifically describing the complete Pholprine fixed-dose combination.
The individual components have different pharmacokinetic profiles:
- Pholcodine is absorbed after oral administration and has a comparatively prolonged duration of action. It undergoes hepatic metabolism and renal elimination.
- Promethazine is orally absorbed, undergoes hepatic metabolism, crosses the blood-brain barrier, and produces clinically important CNS effects. It also crosses the placenta and is distributed into breast milk.
- Phenylpropanolamine is orally absorbed and is eliminated predominantly through the kidneys, with urinary excretion being an important route.
- Tolu syrup is a traditional formulation component rather than an active drug for which clinically important combination pharmacokinetic parameters are established.
Exact values such as Cmax, Tmax, bioavailability, clearance, volume of distribution, or elimination half-life for the Pholprine combination itself should not be inferred from generic individual-drug data. The precise values supplied in some historical descriptions are not sufficiently verified for this product and are therefore omitted.
11. Indications
Historical descriptions of Pholprine identify it as a symptomatic preparation for dry or irritating, non-productive cough, particularly when accompanied by upper-respiratory symptoms such as nasal congestion or rhinorrhea.
The pharmacological components are consistent with such a use:
- pholcodine for cough suppression;
- phenylpropanolamine for nasal decongestion;
- promethazine for antihistaminic symptom relief.
Because current product authorization and labeling could not be independently established, these indications should be regarded as historical product information rather than confirmation of a currently authorized indication in Egypt.
Persistent, recurrent, severe, or unexplained cough requires assessment of the underlying cause rather than prolonged symptomatic suppression.
12. Administration
The product is intended for oral administration.
A definitive current dosing schedule for Pholprine could not be verified from a current primary product label or an authoritative current Egyptian regulatory source. Because the available historical and secondary-source information is insufficient to establish a reliable current pediatric dosing regimen, specific doses are not provided here.
Consequently:
- Do not infer the dose from the concentration of an old online listing.
- Do not substitute a dose from another pholcodine/promethazine combination.
- Use the current approved package insert if a legitimately marketed formulation exists.
- If the product is no longer authorized or available, it should not be used on the basis of historical dosing information.
An accurately calibrated oral measuring device should be used for liquid medicines rather than an ordinary household spoon.
13. Method of Preparation
Pholprine is described as a ready-to-use oral liquid/linctus.
No evidence was identified indicating that the product requires reconstitution before administration.
The bottle should be handled according to the instructions on the specific product label. Any shaking instruction should likewise be taken from the actual formulation's labeling rather than assumed from generic syrup practice.
14. Contraindications
Because the exact current approved label could not be verified, the following should be regarded as ingredient-related major contraindication considerations, rather than a substitute for the official product labeling:
- Hypersensitivity to pholcodine, promethazine, phenylpropanolamine, or another component of the formulation.
- Conditions in which sympathomimetic decongestants are contraindicated or unsuitable, particularly severe or uncontrolled hypertension and significant cardiovascular disease.
- Concurrent or recent treatment with monoamine oxidase inhibitors (MAOIs) because of potentially serious sympathomimetic interactions.
- Significant respiratory depression or severe respiratory compromise, particularly because of the opioid antitussive component.
- Conditions in which promethazine's anticholinergic effects may be hazardous, such as narrow-angle glaucoma or urinary retention.
- Previous serious hypersensitivity to promethazine or other phenothiazine derivatives should be considered relevant to promethazine-containing formulations.
Age-related restrictions must be determined from the specific approved product labeling. The conflicting historical age limits in secondary sources are insufficient evidence for assigning a definitive current pediatric contraindication.
15. Warnings & Precautions
Pholcodine and peri-anaesthetic anaphylaxis
This is the most important contemporary safety issue associated with the formulation.
Evidence reviewed by European and other regulators found that pholcodine exposure, particularly during the 12 months preceding general anaesthesia involving NMBAs, is associated with an increased risk of peri-anaesthetic anaphylaxis to neuromuscular blocking agents. The ALPHO study reported an adjusted odds ratio of approximately 4.2 for this association.
The EMA subsequently recommended withdrawal of pholcodine-containing medicines from the EU market, and the UK withdrew them in 2023. Australia also cancelled the registration of pholcodine-containing medicines.
The EDA itself issued a pharmacovigilance communication concerning this issue and specifically noted the association between pholcodine use within 12 months before anaesthesia and NMBA-related anaphylaxis.
Anyone who has used a pholcodine-containing product should inform the anaesthesiologist before general anaesthesia, particularly when use occurred within the preceding 12 months.
Sedation and CNS depression
Promethazine can cause substantial drowsiness, while pholcodine may contribute to CNS depression. Alcohol, opioids, sedative-hypnotics, benzodiazepines, and other CNS depressants can increase these effects.
Driving and hazardous activities should be avoided if the medicine causes drowsiness or impaired alertness.
Phenylpropanolamine cardiovascular risk
Phenylpropanolamine is a sympathomimetic and can increase blood pressure and heart rate. Its historical association with hemorrhagic stroke led to major regulatory action in the United States and restrictions or withdrawal in multiple markets.
Particular caution is therefore warranted in people with hypertension, cardiovascular disease, cerebrovascular disease, hyperthyroidism, or other conditions in which sympathomimetic effects may be hazardous.
Pediatric use
Young children may be particularly vulnerable to the sedative and respiratory effects of centrally acting cough medicines and first-generation antihistamines. The exact pediatric age restrictions and doses for Pholprine should be taken only from an applicable current approved label.
Duration of use
Cough suppression should not substitute for evaluation of a persistent or worsening cough. Medical assessment is appropriate when cough is prolonged, recurrent, severe, or associated with features such as significant breathlessness, chest pain, haemoptysis, persistent high fever, or other concerning symptoms.
16. Drug Interactions
Important potential interactions arise from the individual ingredients:
- Alcohol and CNS depressants: may substantially increase sedation and CNS/respiratory depression from pholcodine and promethazine.
- Opioids and sedative medicines: may produce additive CNS and respiratory depression.
- MAO inhibitors: can produce clinically significant sympathomimetic interactions with phenylpropanolamine and may also intensify the effects of promethazine.
- Other sympathomimetics/decongestants: may increase cardiovascular stimulation and blood pressure.
- Antihypertensive medicines: sympathomimetic activity may reduce the effectiveness of some antihypertensive therapy.
- Other anticholinergic medicines: may increase dry mouth, blurred vision, constipation, urinary retention, and other anticholinergic effects associated with promethazine.
- Neuromuscular blocking agents: this is a special safety consideration rather than a conventional pharmacokinetic interaction. Previous pholcodine exposure may increase the risk of anaphylaxis to NMBAs during anaesthesia.
Patients should provide healthcare professionals with a complete list of medicines and supplements they are using.
17. Side Effects
Potential adverse effects reflect the pharmacology of the individual components.
Common or clinically recognized effects
- Drowsiness and sedation
- Dizziness
- Dry mouth
- Blurred vision
- Nausea or gastrointestinal discomfort
- Constipation
- Difficulty urinating or urinary retention
- Palpitations or tachycardia
- Increased blood pressure
- Headache
Other possible effects
Promethazine may cause paradoxical excitation, particularly in susceptible children, as well as confusion or marked anticholinergic effects.
Serious hypersensitivity reactions, including angioedema and anaphylaxis, are possible with medicines in general.
Most importantly, pholcodine has a specific peri-operative anaphylaxis association involving NMBAs, which is distinct from an ordinary immediate allergy to the cough medicine itself.
Excessive exposure to opioid-containing preparations may cause clinically significant CNS and respiratory depression.
18. Use in Special Populations
Pediatric patients
Use in children requires particular caution because promethazine and pholcodine can cause significant CNS effects. The precise minimum age and pediatric dosage for a specific Pholprine formulation should be determined from the applicable approved label; conflicting historical online dosing information should not be used to establish a current dose.
Older adults
Older adults may be more susceptible to sedation, confusion, falls, urinary retention, constipation, and anticholinergic effects from promethazine, as well as cardiovascular effects from sympathomimetics.
Pregnancy
Adequate product-specific evidence for the complete Pholprine combination is limited. The individual ingredients have different pregnancy considerations, and phenylpropanolamine and pholcodine should not be assumed to be risk-free.
The historical FDA pregnancy-letter-category terminology should not be used as a current classification system. Pregnancy use should therefore be based on current ingredient-specific evidence and professional assessment rather than an outdated "Category C" designation.
Breastfeeding
Promethazine and opioid-related exposure through breast milk may be clinically relevant, and sympathomimetics may also affect lactation. The safety of the complete combination during breastfeeding has not been adequately established.
Use during breastfeeding should therefore be determined by a healthcare professional after consideration of the individual ingredients and the clinical circumstances.
Renal or hepatic impairment
Because the components undergo hepatic metabolism and/or renal elimination, impaired organ function may alter exposure. Product-specific dose-adjustment data for the complete Pholprine combination were not identified.
Cardiovascular disease and hypertension
The phenylpropanolamine component is particularly relevant because of its sympathomimetic cardiovascular effects. Individuals with hypertension or significant cardiovascular disease require particular caution.
19. Storage Conditions
The product should be stored according to the specific manufacturer's labeling.
General liquid-medicine principles include:
- Keep the container tightly closed.
- Keep out of the reach and sight of children.
- Protect from inappropriate heat and direct light where specified by the label.
- Do not use after the expiry date.
- Do not use a product whose appearance, odor, or physical characteristics have changed unexpectedly.
A definitive storage temperature should not be assigned without the original approved product labeling.
20. Additional Sections
Regulatory and Safety Context
The regulatory history of pholcodine is particularly important when evaluating Pholprine today.
The EMA concluded that pholcodine-containing medicines should be withdrawn from the EU market because of the risk of severe anaphylactic reactions to NMBAs during anaesthesia.
The UK subsequently recalled and withdrew pholcodine-containing medicines in March 2023. The MHRA emphasized the association between pholcodine exposure during the preceding 12 months and peri-anaesthetic anaphylaxis.
Australia similarly cancelled registrations and recalled pholcodine-containing medicines.
Importantly, Egypt has also formally communicated the pholcodine safety issue through the Egyptian Drug Authority's pharmacovigilance system. The EDA communication describes the 2022 ALPHO study and the association between pholcodine exposure within 12 months before anaesthesia and NMBA-related anaphylaxis.
For Pholprine specifically, Egyptian secondary databases identify the product as a Misr 125 mL cough linctus, and at least one current database labels it as cancelled. However, the publicly accessible EDA registered-drug search interface did not provide sufficient searchable information during this review to independently establish the present authorization status of this specific product.
Composition Uncertainty
The exact historical formulation deserves special caution. Current Egyptian secondary sources identify phenylpropanolamine + pholcodine + promethazine + tolu syrup, whereas an older pharmaceutical-list source contains a formulation record involving pseudoephedrine.
Because these records are inconsistent and no current primary label was located, exact ingredient strengths have deliberately not been presented as established facts.
Overdose
Overdose may produce a mixed toxidrome reflecting opioid, antihistaminic/anticholinergic, and sympathomimetic effects. Possible manifestations include marked sedation or CNS depression, respiratory depression, tachycardia, hypertension or hypotension, agitation, anticholinergic effects, and seizures.
Suspected significant overdose requires urgent medical or poison-control assessment, particularly in children.
Management is supportive and directed at the clinical manifestations. In severe opioid-mediated respiratory depression, naloxone may be considered by appropriately trained healthcare professionals. Because this is a multi-ingredient preparation, management must account for the effects of all components rather than treating the exposure as an isolated opioid overdose.
Specific home-treatment instructions, routine gastric lavage, or fixed charcoal timing should not be presented as universal recommendations because the appropriateness of gastrointestinal decontamination depends on the individual exposure, timing, airway status, formulation, and current toxicology guidance.
Evidence and Product-Status Limitation
The EDA maintains official databases and services for registered pharmaceutical products and provides a dedicated service for reliable drug-information inquiries. Its official resources should be used to establish the current Egyptian status of any historical Pholprine product.
21. Frequently Asked Questions (FAQ)
Q1. What is Pholprine Cough Linctus?
Pholprine is a historical Egyptian cough-and-cold preparation associated with Misr and described in Egyptian drug-information sources as containing pholcodine, phenylpropanolamine, promethazine, and tolu syrup.
Q2. Is Pholprine an antibiotic?
No. It is a symptomatic cough-and-cold preparation and has no direct antibacterial, antiviral, or antifungal activity.
Q3. Is Pholprine intended for dry cough?
Historical product descriptions identify it primarily with symptomatic treatment of dry or irritating cough. The exact currently authorized indication, however, should be confirmed against an applicable current product label.
Q4. Why is pholcodine considered an important safety concern?
Pholcodine exposure has been associated with increased risk of anaphylaxis to neuromuscular blocking agents used during general anaesthesia. The association is particularly documented for exposure during the preceding 12 months.
Q5. What should a person tell an anaesthesiologist?
A person who has used a pholcodine-containing medicine should tell the anaesthesiologist before general anaesthesia, particularly if use occurred within the previous 12 months.
Q6. Why is phenylpropanolamine important?
Phenylpropanolamine is a sympathomimetic decongestant with cardiovascular effects. Its historical association with hemorrhagic stroke resulted in major restrictions and removal from many markets.
Q7. Is the exact strength of Pholprine known?
Historical Egyptian sources identify the ingredients, but the exact quantitative formulation could not be reliably verified from a current primary product label during this review. Conflicting historical records exist, so exact mg/5 mL values should not be assumed.
Q8. Is Pholprine currently available in Egypt?
Its current regulatory status could not be conclusively established through the publicly searchable EDA interface during this review. Some Egyptian secondary databases identify the product as cancelled, while other websites continue to display historical product listings. The EDA should be regarded as the authoritative source for current registration and circulation status.
Q9. Can the historical online pediatric doses be relied upon?
No. The available historical data contain inconsistent pediatric dosing information, and a current primary approved label was not identified. A historical online dose should therefore not be treated as an established current dose.
Q10. Can Pholprine be combined with alcohol or sedatives?
This combination is potentially hazardous because promethazine and pholcodine can contribute to CNS depression. Alcohol, opioids, benzodiazepines, sleeping medicines, and other sedatives may increase drowsiness and respiratory-depression risk.
Q11. What should be done after a suspected overdose?
A potentially significant overdose requires urgent professional medical assessment. The combination can produce opioid, antihistaminic/anticholinergic, and sympathomimetic toxicity, and treatment should be based on the clinical presentation.
22. References
-
European Medicines Agency (EMA). Pholcodine-containing medicinal products — referral and withdrawal from the EU market. EMA concluded that pholcodine-containing medicines should be withdrawn because of the risk of anaphylactic reactions to NMBAs during anaesthesia.
-
European Medicines Agency (EMA). Recommendation to withdraw pholcodine medicines from the EU market, December 2022.
-
Medicines and Healthcare products Regulatory Agency (MHRA), UK. Pholcodine-containing cough and cold medicines: withdrawal from the UK market, March 2023. The MHRA reported a significant association between pholcodine use during the preceding 12 months and peri-anaesthetic anaphylaxis to NMBAs.
-
Therapeutic Goods Administration (TGA), Australia. Pholcodine safety action and cancellation of pholcodine-containing medicines.
-
Egyptian Drug Authority (EDA). Pharmacovigilance communication concerning pholcodine-containing medicinal products and the risk of peri-anaesthetic anaphylaxis associated with NMBAs. The EDA communication discusses the ALPHO study and the 12-month exposure period.
-
Egyptian Drug Authority. Official registered-drug search and pharmaceutical regulatory resources.
-
Egyptian Drug Authority. Official information describing the Authority's responsibility for pharmaceutical registration, circulation, quality, efficacy, and safety in Egypt.
-
Egyptian secondary drug-information sources. Historical identification of Pholprine Cough Linctus as a 125 mL Misr product containing phenylpropanolamine, pholcodine, promethazine, and tolu syrup. These sources are useful for historical identification but should not supersede current EDA-approved labeling.
-
Historical Egyptian pharmaceutical product-list data. A separate older record contains a discrepant formulation involving pseudoephedrine, demonstrating why exact historical strengths should not be reconstructed without the original product documentation.
-
U.S. Food and Drug Administration (FDA). Regulatory history concerning phenylpropanolamine and its safety concerns, including hemorrhagic stroke risk and subsequent removal/restriction from OTC use.
Final verification note: Where current primary product information was unavailable or conflicting, the monograph deliberately avoids presenting an uncertain value as fact. In particular, the exact quantitative formulation, current Egyptian marketing authorization status, current availability, and current product-specific dosing should be verified against the applicable EDA record and the original approved manufacturer labeling before publication or clinical reliance.